JP2022544946A5 - - Google Patents
Info
- Publication number
- JP2022544946A5 JP2022544946A5 JP2022509034A JP2022509034A JP2022544946A5 JP 2022544946 A5 JP2022544946 A5 JP 2022544946A5 JP 2022509034 A JP2022509034 A JP 2022509034A JP 2022509034 A JP2022509034 A JP 2022509034A JP 2022544946 A5 JP2022544946 A5 JP 2022544946A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- halo
- enantiomer
- pharmaceutically acceptable
- alkoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025024756A JP2025081505A (ja) | 2019-08-14 | 2025-02-19 | Ｎｓｄ２阻害剤及び抗がん剤としてのピペリジニル－メチル－プリンアミン |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2019/100542 | 2019-08-14 | ||
| PCT/CN2019/100542 WO2021026803A1 (en) | 2019-08-14 | 2019-08-14 | Piperidinyl-methyl-purineamines as nsd2 inhibitors and anti-cancer agents |
| PCT/IB2020/057602 WO2021028854A1 (en) | 2019-08-14 | 2020-08-12 | Piperidinyl-methyl-purineamines as nsd2 inhibitors and anti-cancer agents |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025024756A Division JP2025081505A (ja) | 2019-08-14 | 2025-02-19 | Ｎｓｄ２阻害剤及び抗がん剤としてのピペリジニル－メチル－プリンアミン |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022544946A JP2022544946A (ja) | 2022-10-24 |
| JP2022544946A5 true JP2022544946A5 (https=) | 2023-08-21 |
| JP7638960B2 JP7638960B2 (ja) | 2025-03-04 |
Family
ID=72145436
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022509034A Active JP7638960B2 (ja) | 2019-08-14 | 2020-08-12 | Ｎｓｄ２阻害剤及び抗がん剤としてのピペリジニル－メチル－プリンアミン |
| JP2025024756A Pending JP2025081505A (ja) | 2019-08-14 | 2025-02-19 | Ｎｓｄ２阻害剤及び抗がん剤としてのピペリジニル－メチル－プリンアミン |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025024756A Pending JP2025081505A (ja) | 2019-08-14 | 2025-02-19 | Ｎｓｄ２阻害剤及び抗がん剤としてのピペリジニル－メチル－プリンアミン |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US11420970B1 (https=) |
| EP (2) | EP4013755B1 (https=) |
| JP (2) | JP7638960B2 (https=) |
| KR (1) | KR102946008B1 (https=) |
| CN (1) | CN114585622B (https=) |
| AU (1) | AU2020328919A1 (https=) |
| BR (1) | BR112022002520A2 (https=) |
| CO (1) | CO2022002804A2 (https=) |
| DK (1) | DK4013755T3 (https=) |
| EC (1) | ECSP22019360A (https=) |
| ES (1) | ES3023540T3 (https=) |
| FI (1) | FI4013755T3 (https=) |
| IL (2) | IL289754B2 (https=) |
| MX (1) | MX2022001784A (https=) |
| MY (1) | MY209614A (https=) |
| PH (1) | PH12022550343A1 (https=) |
| PL (1) | PL4013755T3 (https=) |
| PT (1) | PT4013755T (https=) |
| WO (2) | WO2021026803A1 (https=) |
| ZA (1) | ZA202200519B (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021026803A1 (en) * | 2019-08-14 | 2021-02-18 | Novartis Ag | Piperidinyl-methyl-purineamines as nsd2 inhibitors and anti-cancer agents |
| DK4013756T3 (da) * | 2019-09-20 | 2024-05-27 | Novartis Ag | MLL1-inhibitorer og anticancermidler |
| JP2025504379A (ja) * | 2022-01-05 | 2025-02-12 | ケイ３６・セラピューティクス・インコーポレイテッド | 重水素濃縮ピペリジニル－メチル－プリンアミン及び関連化合物、ならびに疾患及び状態の治療におけるそれらの使用 |
| IL314895A (en) * | 2022-02-16 | 2024-10-01 | Duke Street Bio Ltd | Pharmaceutical compound |
| WO2023225150A1 (en) * | 2022-05-18 | 2023-11-23 | K36 Therapeutics, Inc. | Piperidinyl-methyl-purine amine fumaric acid salts, crystalline forms, and their use in treating medical diseases and conditions |
| US20250326752A1 (en) * | 2022-05-18 | 2025-10-23 | K36 Therapeutics, Inc. | Piperidinyl-methyl-purine amine salts, crystalline forms, and their use in treating medical diseases and conditions |
| AU2023273656A1 (en) * | 2022-05-18 | 2024-11-28 | K36 Therapeutics, Inc. | Piperidinyl-methyl-purine amine d-tartaric acid salts, crystalline forms, and their use in treating medical diseases and conditions |
| WO2023225144A1 (en) * | 2022-05-18 | 2023-11-23 | K36 Therapeutics, Inc. | Piperidinyl-methyl-purine amine salts, crystalline forms, and their use in treating medical diseases and conditions |
| WO2023230038A1 (en) * | 2022-05-23 | 2023-11-30 | K36 Therapeutics, Inc. | Piperidinyl-methylpurine pyrimidines and related compounds and their use in treating diseases and conditions |
| US20250361235A1 (en) * | 2022-05-23 | 2025-11-27 | K36 Therapeutics, Inc. | Piperidinyl-methylpurine benzenes and related compounds and their use in treating diseases and conditions |
| WO2024073283A1 (en) * | 2022-09-26 | 2024-04-04 | Board Of Regents, The University Of Texas System | Heterocycles as modulators of nsd activity |
| JP2025530501A (ja) * | 2022-09-26 | 2025-09-11 | ボード オブ レジェンツ，ザ ユニバーシティ オブ テキサス システム | Ｎｓｄ活性の修飾物質としての複素環 |
| KR20250129690A (ko) * | 2022-12-12 | 2025-08-29 | 케이36 테라퓨틱스, 인크. | 피페리딘일-메틸-푸린 아민을 함유하는 약학적 조성물과 질환 및 병태 치료에서 이의 용도 |
| WO2025106786A1 (en) * | 2023-11-17 | 2025-05-22 | K36 Therapeutics, Inc. | Deuterium-enriched piperidinyl-methyl-purine amine salts, crystalline forms, and their use in treating medical diseases and conditions |
| CN117720550A (zh) * | 2023-12-14 | 2024-03-19 | 深圳市华先医药科技有限公司 | (s)-3-甲基-4-氧代-2-氧杂-8-氮杂螺[4.5]癸烷-8-甲酸叔丁酯合成方法 |
| CN117843641B (zh) * | 2023-12-28 | 2025-04-25 | 和径医药科技（上海）有限公司 | Nsd3抑制剂及其制备方法和应用 |
| WO2025147514A1 (en) * | 2024-01-02 | 2025-07-10 | K36 Therapeutics, Inc. | Piperidinyl-methyl-purineamine nsd2 inhibitor therapeutic methods and compositions for treating cancer |
| CN118459395A (zh) * | 2024-05-10 | 2024-08-09 | 南通大学 | 一种5-(叔丁氧羰基氨基)哌啶-3-羧酸甲酯的合成方法 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7157465B2 (en) | 2001-04-17 | 2007-01-02 | Dainippon Simitomo Pharma Co., Ltd. | Adenine derivatives |
| US7332486B2 (en) * | 2002-08-08 | 2008-02-19 | Memory Pharmaceuticals Corp. | Phosphodiesterase 4 inhibitors |
| MXPA05003193A (es) * | 2002-09-27 | 2005-06-08 | Sumitomo Pharma | Compuesto de adenina novedoso y uso del mismo. |
| JP2004137157A (ja) * | 2002-10-16 | 2004-05-13 | Sumitomo Pharmaceut Co Ltd | 新規アデニン誘導体を有効成分として含有する医薬 |
| JP2007269629A (ja) | 2004-06-21 | 2007-10-18 | Astellas Pharma Inc | キナゾリン誘導体 |
| AR065784A1 (es) | 2007-03-20 | 2009-07-01 | Dainippon Sumitomo Pharma Co | Derivados de 8-oxo adenina,medicamentos que los contienen y usos como agentes terapeuticos para enfermedades alergicas, antivirales o antibacterianas. |
| JP5694345B2 (ja) * | 2009-10-22 | 2015-04-01 | ギリアード サイエンシーズ， インコーポレイテッド | Ｔｏｌｌ様受容体の調節因子 |
| GB201204985D0 (en) | 2012-03-21 | 2012-05-02 | Genentech Inc | Compounds |
| WO2019196918A1 (zh) | 2018-04-13 | 2019-10-17 | 罗欣药业(上海)有限公司 | 五元杂环并嘧啶类化合物、药物组合物及用途 |
| CN109223794B (zh) * | 2018-08-24 | 2020-07-28 | 江苏理工学院 | 一种化合物c6作为组蛋白甲基转移酶nsd3活性抑制剂及其应用 |
| CN108853110B (zh) | 2018-08-24 | 2020-07-28 | 江苏理工学院 | 一种化合物a8作为组蛋白甲基转移酶nsd3活性抑制剂及其应用 |
| WO2021026803A1 (en) * | 2019-08-14 | 2021-02-18 | Novartis Ag | Piperidinyl-methyl-purineamines as nsd2 inhibitors and anti-cancer agents |
| JP2025504379A (ja) | 2022-01-05 | 2025-02-12 | ケイ３６・セラピューティクス・インコーポレイテッド | 重水素濃縮ピペリジニル－メチル－プリンアミン及び関連化合物、ならびに疾患及び状態の治療におけるそれらの使用 |
| AU2023273656A1 (en) | 2022-05-18 | 2024-11-28 | K36 Therapeutics, Inc. | Piperidinyl-methyl-purine amine d-tartaric acid salts, crystalline forms, and their use in treating medical diseases and conditions |
| WO2023225144A1 (en) | 2022-05-18 | 2023-11-23 | K36 Therapeutics, Inc. | Piperidinyl-methyl-purine amine salts, crystalline forms, and their use in treating medical diseases and conditions |
| US20250326752A1 (en) | 2022-05-18 | 2025-10-23 | K36 Therapeutics, Inc. | Piperidinyl-methyl-purine amine salts, crystalline forms, and their use in treating medical diseases and conditions |
| WO2023225150A1 (en) | 2022-05-18 | 2023-11-23 | K36 Therapeutics, Inc. | Piperidinyl-methyl-purine amine fumaric acid salts, crystalline forms, and their use in treating medical diseases and conditions |
-
2019
- 2019-08-14 WO PCT/CN2019/100542 patent/WO2021026803A1/en not_active Ceased
-
2020
- 2020-08-12 MY MYPI2022000244A patent/MY209614A/en unknown
- 2020-08-12 WO PCT/IB2020/057602 patent/WO2021028854A1/en not_active Ceased
- 2020-08-12 CN CN202080069611.5A patent/CN114585622B/zh active Active
- 2020-08-12 KR KR1020227008255A patent/KR102946008B1/ko active Active
- 2020-08-12 ES ES20757967T patent/ES3023540T3/es active Active
- 2020-08-12 PT PT207579673T patent/PT4013755T/pt unknown
- 2020-08-12 BR BR112022002520A patent/BR112022002520A2/pt unknown
- 2020-08-12 EP EP20757967.3A patent/EP4013755B1/en active Active
- 2020-08-12 PH PH1/2022/550343A patent/PH12022550343A1/en unknown
- 2020-08-12 IL IL289754A patent/IL289754B2/en unknown
- 2020-08-12 FI FIEP20757967.3T patent/FI4013755T3/fi active
- 2020-08-12 JP JP2022509034A patent/JP7638960B2/ja active Active
- 2020-08-12 AU AU2020328919A patent/AU2020328919A1/en active Pending
- 2020-08-12 EP EP25150251.4A patent/EP4559915A1/en active Pending
- 2020-08-12 DK DK20757967.3T patent/DK4013755T3/da active
- 2020-08-12 MX MX2022001784A patent/MX2022001784A/es unknown
- 2020-08-12 PL PL20757967.3T patent/PL4013755T3/pl unknown
- 2020-08-12 IL IL320143A patent/IL320143A/en unknown
-
2021
- 2021-05-21 US US17/327,226 patent/US11420970B1/en active Active
-
2022
- 2022-01-11 ZA ZA2022/00519A patent/ZA202200519B/en unknown
- 2022-03-10 CO CONC2022/0002804A patent/CO2022002804A2/es unknown
- 2022-03-14 EC ECSENADI202219360A patent/ECSP22019360A/es unknown
- 2022-05-09 US US17/739,855 patent/US12312353B2/en active Active
-
2025
- 2025-02-19 JP JP2025024756A patent/JP2025081505A/ja active Pending
- 2025-05-20 US US19/213,478 patent/US20250276971A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022544946A5 (https=) | ||
| JP7536761B2 (ja) | 抗ウイルス剤としての官能化複素環 | |
| US20250122222A1 (en) | Heterocyclic compounds and methods of use | |
| ES2648876T3 (es) | Dihidropirido[3,4-b]pirazinonas sustituidas como inhibidores duales de proteínas BET y quinasas tipo polo | |
| CN104119350B (zh) | 氨基喹唑啉类衍生物及其盐和使用方法 | |
| US9453007B2 (en) | Hepatitis C inhibitors and uses thereof | |
| CN112204027A (zh) | Erk 抑制剂及其应用 | |
| CN104211692B (zh) | 作为欧若拉激酶抑制剂的衍生物 | |
| KR20190080897A (ko) | 치환된 피리디논 함유 트리시클릭 화합물, 및 그의 사용 방법 | |
| RU2014153627A (ru) | Имидазо[1, 2-]пиридазиновые производные как ингибиторы киназ | |
| ME02202B (me) | Jedinjenja pirolopirimidina kao inhibitori cdk4/6 | |
| JP2016106095A (ja) | イミダゾピロリジノン化合物 | |
| PE20090370A1 (es) | Derivados de heterociclo fusionado como inhibidores de quinasa | |
| JP2012528828A5 (https=) | ||
| EP3197883A1 (en) | Novel compounds | |
| JP2012525430A5 (https=) | ||
| JP2014530238A5 (https=) | ||
| RU2014119250A (ru) | Производные 8-карбамоил-2-(2,3-дизамещенного пирид-6-ил)-1,2,3,4-тетрагидроизохинолина в качестве индуцирующих апоптоз средств для лечения рака и иммунных и аутоиммунных заболеваний | |
| WO2010016490A1 (ja) | イミダゾピリジン－２－オン誘導体 | |
| JP2009539878A5 (https=) | ||
| JP2016538316A5 (https=) | ||
| JP2016523974A5 (https=) | ||
| PT2758401T (pt) | Imidazopiridazinas amino-substituídas | |
| JP2018515525A5 (https=) | ||
| CA2571627A1 (en) | Substituted aryl-amine derivatives and methods of use |